Literature DB >> 20573925

Early use of TIPS in patients with cirrhosis and variceal bleeding.

Juan Carlos García-Pagán1, Karel Caca, Christophe Bureau, Wim Laleman, Beate Appenrodt, Angelo Luca, Juan G Abraldes, Frederik Nevens, Jean Pierre Vinel, Joachim Mössner, Jaime Bosch.   

Abstract

BACKGROUND: Patients with cirrhosis in Child-Pugh class C or those in class B who have persistent bleeding at endoscopy are at high risk for treatment failure and a poor prognosis, even if they have undergone rescue treatment with a transjugular intrahepatic portosystemic shunt (TIPS). This study evaluated the earlier use of TIPS in such patients.
METHODS: We randomly assigned, within 24 hours after admission, a total of 63 patients with cirrhosis and acute variceal bleeding who had been treated with vasoactive drugs plus endoscopic therapy to treatment with a polytetrafluoroethylene-covered stent within 72 hours after randomization (early-TIPS group, 32 patients) or continuation of vasoactive-drug therapy, followed after 3 to 5 days by treatment with propranolol or nadolol and long-term endoscopic band ligation (EBL), with insertion of a TIPS if needed as rescue therapy (pharmacotherapy-EBL group, 31 patients).
RESULTS: During a median follow-up of 16 months, rebleeding or failure to control bleeding occurred in 14 patients in the pharmacotherapy-EBL group as compared with 1 patient in the early-TIPS group (P=0.001). The 1-year actuarial probability of remaining free of this composite end point was 50% in the pharmacotherapy-EBL group versus 97% in the early-TIPS group (P<0.001). Sixteen patients died (12 in the pharmacotherapy-EBL group and 4 in the early-TIPS group, P=0.01). The 1-year actuarial survival was 61% in the pharmacotherapy-EBL group versus 86% in the early-TIPS group (P<0.001). Seven patients in the pharmacotherapy-EBL group received TIPS as rescue therapy, but four died. The number of days in the intensive care unit and the percentage of time in the hospital during follow-up were significantly higher in the pharmacotherapy-EBL group than in the early-TIPS group. No significant differences were observed between the two treatment groups with respect to serious adverse events.
CONCLUSIONS: In these patients with cirrhosis who were hospitalized for acute variceal bleeding and at high risk for treatment failure, the early use of TIPS was associated with significant reductions in treatment failure and in mortality. (Current Controlled Trials number, ISRCTN58150114.) 2010 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20573925     DOI: 10.1056/NEJMoa0910102

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  259 in total

1.  Transjugular intrahepatic porto-systemic shunt in the elderly: Palliation for complications of portal hypertension.

Authors:  Mubin I Syed; Hetal Karsan; Hector Ferral; Azim Shaikh; Uzma Waheed; Talal Akhter; Alan Gabbard; Kamal Morar; Robert Tyrrell
Journal:  World J Hepatol       Date:  2012-02-27

Review 2.  [Classification and management of upper gastrointestinal bleeding].

Authors:  K Herrlinger
Journal:  Internist (Berl)       Date:  2010-09       Impact factor: 0.743

3.  Addition of Somatostatin After Successful Endoscopic Variceal Ligation Does not Prevent Early Rebleeding in Comparison to Placebo: A Double Blind Randomized Controlled Trial.

Authors:  Ashish Kumar; Sanjeev K Jha; Vibhu V Mittal; Praveen Sharma; Barjesh C Sharma; Shiv K Sarin
Journal:  J Clin Exp Hepatol       Date:  2015-06-16

4.  Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Jian-Bo Zhao; Chao Feng; Qiao-Hua Zhu; Xiao-Feng He; Yan-Hao Li; Yong Chen
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

Review 5.  Role of prophylactic antibiotics in cirrhotic patients with variceal bleeding.

Authors:  Yeong Yeh Lee; Hoi-Poh Tee; Sanjiv Mahadeva
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

6.  Management of Acute Variceal Hemorrhage as a Model of Individualized Care for Patients With Cirrhosis.

Authors:  Guadalupe Garcia-Tsao
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-01       Impact factor: 11.382

7.  Delayed liver laceration following transjugular intrahepatic portosystemic shunt for portal hypertension.

Authors:  Kai Liu; Xin-Xin Fan; Xu-Lin Wang; Chang-Sheng He; Xing-Jiang Wu
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

8.  Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding.

Authors:  Hui Xue; Meng Zhang; Jack Xq Pang; Fei Yan; Ying-Chao Li; Liang-Shan Lv; Jia Yuan; Muna Palikhe; Wei-Zhi Li; Zhi-Lun Wang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

Review 9.  Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.

Authors:  Sith Siramolpiwat
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 10.  Transjugular intrahepatic portosystemic shunt in liver transplant recipients: indications, feasibility, and outcomes.

Authors:  Bin Chen; Weiping Wang; Matthew D Tam; Cristiano Quintini; John J Fung; Xiao Li
Journal:  Hepatol Int       Date:  2015-04-26       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.